Dublin, Dec. 26, 2024 (GLOBE NEWSWIRE) -- The "Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) - Global Clinical Trials Review, 2024" clinical trials has been added to ResearchAndMarkets.com's ...

DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) - Pipeline Review, H2 2016" report to their offering. Dravet ...

DUBLIN--(BUSINESS WIRE)--The "Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) Ongoing Global Clinical Trials Analysis and Outlook" report has been added to ResearchAndMarkets.com's offering.

Etomidate is widely used for induction in general anaesthesia due to its stability in haemodynamics and rapid onset of action. However, its use is frequently complicated by the occurrence of myoclonus ...

STEVENAGE, England--(BUSINESS WIRE)--Autifony Therapeutics Limited (“Autifony”), which is pioneering the development of novel pharmaceutical treatments for rare CNS disorders and other serious brain ...

(MENAFN- GlobeNewsWire - Nasdaq) Company Coverage includes Jazz Pharmaceuticals, UCB, Takeda Pharmaceutical, Biocodex, Longboard Pharmaceuticals, Stoke Therapeutics, Thermo Fisher Scientific, Harmony ...